Daiken Biomedical Co (TPE:7780) Ending Cash Position: NT$5,261 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:7780 Daiken Biomedical Co Ltd TPE:7780
23 GF Score
Price NT$17.10
! 4 Warning Signs
View Full Analysis

What is Daiken Biomedical Co Ending Cash Position?

Daiken Biomedical Co TPE:7780 +1.48% 23 Ending Cash Position is NT$5,261 Mil as of Jun. 2026. GuruFocus rates TPE:7780 with a GF Score™ of 23/100. The stock has 4 warning signs investors should review.

Daiken Biomedical Co's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$5,261 Mil.

Daiken Biomedical Co's quarterly Ending Cash Position increased from Dec. 2025 (NT$2,236 Mil) to Mar. 2026 (NT$5,433 Mil) but then declined from Mar. 2026 (NT$5,433 Mil) to Jun. 2026 (NT$5,261 Mil).

Daiken Biomedical Co's annual Ending Cash Position increased from Dec. 2023 (NT$287 Mil) to Dec. 2024 (NT$1,140 Mil) and increased from Dec. 2024 (NT$1,140 Mil) to Dec. 2025 (NT$2,236 Mil).

Daiken Biomedical Co Ending Cash Position Related Terms

Daiken Biomedical Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Daiken Biomedical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daiken Biomedical Co Ending Cash Position Chart

Daiken Biomedical Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Ending Cash Position
243.71 287.07 1,139.72 2,236.29

Daiken Biomedical Co Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,189.02 3,662.73 2,236.29 5,433.25 5,261.10
TPE:7780
23GF Score
Daiken Biomedical Co Ltd TPE:7780
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Daiken Biomedical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Daiken Biomedical Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1139.724+1096.566
=2,236

Daiken Biomedical Co's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5433.253+-172.155
=5,261

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$5,261 Mil mean?
Daiken Biomedical Co (TPE:7780) has a Ending Cash Position of NT$5,261 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Daiken Biomedical Co and its competitors.
Is Daiken Biomedical Co's Ending Cash Position too high?
Daiken Biomedical Co's current Ending Cash Position is NT$5,261 Mil. Overall, Daiken Biomedical Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Daiken Biomedical Co's Ending Cash Position compare to KHC and GIS?
Daiken Biomedical Co's Ending Cash Position of NT$5,261 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Consumer Packaged Goods company?
A good Ending Cash Position depends on the Consumer Packaged Goods industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Daiken Biomedical Co and its competitors. Daiken Biomedical Co's current Ending Cash Position is NT$5,261 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiken Biomedical Co stock overvalued right now?
Daiken Biomedical Co (TPE:7780) has a current Ending Cash Position of NT$5,261 Mil. The current Ending Cash Position is NT$5,261 Mil. Daiken Biomedical Co's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Daiken Biomedical Co (TPE:7780), the current Ending Cash Position is NT$5,261 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Daiken Biomedical Co Business Description

Address Roosevelt Road, 12th Floor, No. 37, Section 3, Daan District, Taipei, TWN
Daiken Biomedical Co Ltd is engaged in Research, development, and sales of health food. Its products include fish oil capsules, collagen powder, collagen drinks, natto capsules, and mint leaf capsules. The companies reportable operating segment consists solely of the e-commerce division.
23GF Score

Get the complete analysis for TPE:7780

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.10
Price